GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

Home
/
update
/
details

Redcliffe Labs Announces Leadership Transition to Drive Healthcare Accessibility

NextEdge Admin

17 Dec 2024

2 min 30 sec

Redcliffe Labs, a leading pan-India omnichannel diagnostics service provider, has announced a key leadership transition to advance its mission of democratizing access to quality diagnostics across India. Co-founder Aditya Kandoi has been appointed Chief Executive Officer (CEO), while Dheeraj Jain assumes the role of Chairman of the Board.

In his new role, Aditya Kandoi aims to amplify Redcliffe Labs' vision of "Giving every Indian the Right to Quality Diagnostics." Addressing critical gaps in healthcare accessibility, Aditya has introduced a strategic framework centered on four pillars: awareness, affordability, accuracy, and accessibility. The company will drive targeted campaigns to promote preventive care while delivering high-quality diagnostics to underserved populations. Aditya’s leadership will focus on expanding Redcliffe Labs’ services beyond metro and Tier I cities to Tier II, III, and IV regions.

“At Redcliffe Labs, we are committed to redefining healthcare accessibility through innovation and operational excellence,” said Aditya Kandoi. “Our goal is to empower individuals across Bharat with quality diagnostics, enabling them to take control of their health.”

Dheeraj Jain, transitioning to Chairman of the Board after six years as CEO, will provide strategic oversight and mentorship to guide Redcliffe Labs through its next phase of growth. “Aditya’s visionary leadership will propel Redcliffe Labs to new heights as we continue to innovate and redefine healthcare standards nationwide,” he said.

Founded in 2018, Redcliffe Labs has rapidly grown into a premier diagnostics provider, operating 80+ labs, 2,000+ collection centers, and home collection services across 220+ cities, serving over 7 million patients to date.